Report Thumbnail
Product Code LP0913613474XS1
Published Date 2023/5/11
English108 PagesGlobal

Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Market Growth 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0913613474XS1◆The May 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/5/11
English 108 PagesGlobal

Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Market Growth 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

The global Pharmaceutical Grade Dexmedetomidine Hydrochloride market size is projected to grow from US$ 249.5 million in 2022 to US$ 388.6 million in 2029; it is expected to grow at a CAGR of 6.5% from 2023 to 2029.
United States market for Pharmaceutical Grade Dexmedetomidine Hydrochloride is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Pharmaceutical Grade Dexmedetomidine Hydrochloride is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Pharmaceutical Grade Dexmedetomidine Hydrochloride is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Pharmaceutical Grade Dexmedetomidine Hydrochloride players cover Moehs Iberica Sl, Gland Pharma Ltd, Emcure Pharmaceuticals Ltd, Interquim Sa De Cv, Sterling Wisconsin Llc, Fermion Oy, Guang'An Kingday Pharma And Chem Co Ltd, Jiangsu Hengrui Pharmaceuticals Co Ltd and Asymchem Laboratories Tianjin Co Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Pharmaceutical Grade Dexmedetomidine Hydrochloride Industry Forecast” looks at past sales and reviews total world Pharmaceutical Grade Dexmedetomidine Hydrochloride sales in 2022, providing a comprehensive analysis by region and market sector of projected Pharmaceutical Grade Dexmedetomidine Hydrochloride sales for 2023 through 2029. With Pharmaceutical Grade Dexmedetomidine Hydrochloride sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pharmaceutical Grade Dexmedetomidine Hydrochloride industry.
This Insight Report provides a comprehensive analysis of the global Pharmaceutical Grade Dexmedetomidine Hydrochloride landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pharmaceutical Grade Dexmedetomidine Hydrochloride portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pharmaceutical Grade Dexmedetomidine Hydrochloride market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pharmaceutical Grade Dexmedetomidine Hydrochloride and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pharmaceutical Grade Dexmedetomidine Hydrochloride.
This report presents a comprehensive overview, market shares, and growth opportunities of Pharmaceutical Grade Dexmedetomidine Hydrochloride market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Purity≥99%
Purity<99%
Segmentation by application
Injection
Nasal Preparations
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Moehs Iberica Sl
Gland Pharma Ltd
Emcure Pharmaceuticals Ltd
Interquim Sa De Cv
Sterling Wisconsin Llc
Fermion Oy
Guang'An Kingday Pharma And Chem Co Ltd
Jiangsu Hengrui Pharmaceuticals Co Ltd
Asymchem Laboratories Tianjin Co Ltd
CommScope Pharmaceuticals
Jiangsu Nhua Pharmaceutical
Sichuan Ren'an Pharmaceutical
Sichuan Xinkaiyuan Pharmaceutical
Jiangsu Huatai Chenguang Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Pharmaceutical Grade Dexmedetomidine Hydrochloride market?
What factors are driving Pharmaceutical Grade Dexmedetomidine Hydrochloride market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pharmaceutical Grade Dexmedetomidine Hydrochloride market opportunities vary by end market size?
How does Pharmaceutical Grade Dexmedetomidine Hydrochloride break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Pharmaceutical Grade Dexmedetomidine Hydrochloride by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Pharmaceutical Grade Dexmedetomidine Hydrochloride by Country/Region, 2018, 2022 & 2029
    • 2.2 Pharmaceutical Grade Dexmedetomidine Hydrochloride Segment by Type
      • 2.2.1 Purity≥99%
      • 2.2.2 Purity<99%
    • 2.3 Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Type
      • 2.3.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Sale Price by Type (2018-2023)
    • 2.4 Pharmaceutical Grade Dexmedetomidine Hydrochloride Segment by Application
      • 2.4.1 Injection
      • 2.4.2 Nasal Preparations
      • 2.4.3 Others
    • 2.5 Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Application
      • 2.5.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Sale Price by Application (2018-2023)
  • 3 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride by Company

    • 3.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Breakdown Data by Company
      • 3.1.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Annual Sales by Company (2018-2023)
      • 3.1.2 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales Market Share by Company (2018-2023)
    • 3.2 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Revenue by Company (2018-2023)
      • 3.2.2 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Revenue Market Share by Company (2018-2023)
    • 3.3 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Sale Price by Company
    • 3.4 Key Manufacturers Pharmaceutical Grade Dexmedetomidine Hydrochloride Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Location Distribution
      • 3.4.2 Players Pharmaceutical Grade Dexmedetomidine Hydrochloride Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Pharmaceutical Grade Dexmedetomidine Hydrochloride by Geographic Region

    • 4.1 World Historic Pharmaceutical Grade Dexmedetomidine Hydrochloride Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Pharmaceutical Grade Dexmedetomidine Hydrochloride Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales Growth
    • 4.4 APAC Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales Growth
    • 4.5 Europe Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales Growth
    • 4.6 Middle East & Africa Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales Growth
  • 5 Americas

    • 5.1 Americas Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Country
      • 5.1.1 Americas Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Country (2018-2023)
      • 5.1.2 Americas Pharmaceutical Grade Dexmedetomidine Hydrochloride Revenue by Country (2018-2023)
    • 5.2 Americas Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Type
    • 5.3 Americas Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Region
      • 6.1.1 APAC Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Region (2018-2023)
      • 6.1.2 APAC Pharmaceutical Grade Dexmedetomidine Hydrochloride Revenue by Region (2018-2023)
    • 6.2 APAC Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Type
    • 6.3 APAC Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan
  • 7 Europe

    • 7.1 Europe Pharmaceutical Grade Dexmedetomidine Hydrochloride by Country
      • 7.1.1 Europe Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Country (2018-2023)
      • 7.1.2 Europe Pharmaceutical Grade Dexmedetomidine Hydrochloride Revenue by Country (2018-2023)
    • 7.2 Europe Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Type
    • 7.3 Europe Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Pharmaceutical Grade Dexmedetomidine Hydrochloride by Country
      • 8.1.1 Middle East & Africa Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Pharmaceutical Grade Dexmedetomidine Hydrochloride Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Type
    • 8.3 Middle East & Africa Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Pharmaceutical Grade Dexmedetomidine Hydrochloride
    • 10.3 Manufacturing Process Analysis of Pharmaceutical Grade Dexmedetomidine Hydrochloride
    • 10.4 Industry Chain Structure of Pharmaceutical Grade Dexmedetomidine Hydrochloride
  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Pharmaceutical Grade Dexmedetomidine Hydrochloride Distributors
    • 11.3 Pharmaceutical Grade Dexmedetomidine Hydrochloride Customer
  • 12 World Forecast Review for Pharmaceutical Grade Dexmedetomidine Hydrochloride by Geographic Region

    • 12.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Market Size Forecast by Region
      • 12.1.1 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Forecast by Region (2024-2029)
      • 12.1.2 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Forecast by Type
    • 12.7 Global Pharmaceutical Grade Dexmedetomidine Hydrochloride Forecast by Application
  • 13 Key Players Analysis

    • 13.1 Moehs Iberica Sl
      • 13.1.1 Moehs Iberica Sl Company Information
      • 13.1.2 Moehs Iberica Sl Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.1.3 Moehs Iberica Sl Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 Moehs Iberica Sl Main Business Overview
      • 13.1.5 Moehs Iberica Sl Latest Developments
    • 13.2 Gland Pharma Ltd
      • 13.2.1 Gland Pharma Ltd Company Information
      • 13.2.2 Gland Pharma Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.2.3 Gland Pharma Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Gland Pharma Ltd Main Business Overview
      • 13.2.5 Gland Pharma Ltd Latest Developments
    • 13.3 Emcure Pharmaceuticals Ltd
      • 13.3.1 Emcure Pharmaceuticals Ltd Company Information
      • 13.3.2 Emcure Pharmaceuticals Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.3.3 Emcure Pharmaceuticals Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 Emcure Pharmaceuticals Ltd Main Business Overview
      • 13.3.5 Emcure Pharmaceuticals Ltd Latest Developments
    • 13.4 Interquim Sa De Cv
      • 13.4.1 Interquim Sa De Cv Company Information
      • 13.4.2 Interquim Sa De Cv Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.4.3 Interquim Sa De Cv Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Interquim Sa De Cv Main Business Overview
      • 13.4.5 Interquim Sa De Cv Latest Developments
    • 13.5 Sterling Wisconsin Llc
      • 13.5.1 Sterling Wisconsin Llc Company Information
      • 13.5.2 Sterling Wisconsin Llc Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.5.3 Sterling Wisconsin Llc Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.5.4 Sterling Wisconsin Llc Main Business Overview
      • 13.5.5 Sterling Wisconsin Llc Latest Developments
    • 13.6 Fermion Oy
      • 13.6.1 Fermion Oy Company Information
      • 13.6.2 Fermion Oy Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.6.3 Fermion Oy Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.6.4 Fermion Oy Main Business Overview
      • 13.6.5 Fermion Oy Latest Developments
    • 13.7 Guang'An Kingday Pharma And Chem Co Ltd
      • 13.7.1 Guang'An Kingday Pharma And Chem Co Ltd Company Information
      • 13.7.2 Guang'An Kingday Pharma And Chem Co Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.7.3 Guang'An Kingday Pharma And Chem Co Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.7.4 Guang'An Kingday Pharma And Chem Co Ltd Main Business Overview
      • 13.7.5 Guang'An Kingday Pharma And Chem Co Ltd Latest Developments
    • 13.8 Jiangsu Hengrui Pharmaceuticals Co Ltd
      • 13.8.1 Jiangsu Hengrui Pharmaceuticals Co Ltd Company Information
      • 13.8.2 Jiangsu Hengrui Pharmaceuticals Co Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.8.3 Jiangsu Hengrui Pharmaceuticals Co Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.8.4 Jiangsu Hengrui Pharmaceuticals Co Ltd Main Business Overview
      • 13.8.5 Jiangsu Hengrui Pharmaceuticals Co Ltd Latest Developments
    • 13.9 Asymchem Laboratories Tianjin Co Ltd
      • 13.9.1 Asymchem Laboratories Tianjin Co Ltd Company Information
      • 13.9.2 Asymchem Laboratories Tianjin Co Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.9.3 Asymchem Laboratories Tianjin Co Ltd Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.9.4 Asymchem Laboratories Tianjin Co Ltd Main Business Overview
      • 13.9.5 Asymchem Laboratories Tianjin Co Ltd Latest Developments
    • 13.10 CommScope Pharmaceuticals
      • 13.10.1 CommScope Pharmaceuticals Company Information
      • 13.10.2 CommScope Pharmaceuticals Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.10.3 CommScope Pharmaceuticals Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.10.4 CommScope Pharmaceuticals Main Business Overview
      • 13.10.5 CommScope Pharmaceuticals Latest Developments
    • 13.11 Jiangsu Nhua Pharmaceutical
      • 13.11.1 Jiangsu Nhua Pharmaceutical Company Information
      • 13.11.2 Jiangsu Nhua Pharmaceutical Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.11.3 Jiangsu Nhua Pharmaceutical Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.11.4 Jiangsu Nhua Pharmaceutical Main Business Overview
      • 13.11.5 Jiangsu Nhua Pharmaceutical Latest Developments
    • 13.12 Sichuan Ren'an Pharmaceutical
      • 13.12.1 Sichuan Ren'an Pharmaceutical Company Information
      • 13.12.2 Sichuan Ren'an Pharmaceutical Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.12.3 Sichuan Ren'an Pharmaceutical Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.12.4 Sichuan Ren'an Pharmaceutical Main Business Overview
      • 13.12.5 Sichuan Ren'an Pharmaceutical Latest Developments
    • 13.13 Sichuan Xinkaiyuan Pharmaceutical
      • 13.13.1 Sichuan Xinkaiyuan Pharmaceutical Company Information
      • 13.13.2 Sichuan Xinkaiyuan Pharmaceutical Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.13.3 Sichuan Xinkaiyuan Pharmaceutical Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.13.4 Sichuan Xinkaiyuan Pharmaceutical Main Business Overview
      • 13.13.5 Sichuan Xinkaiyuan Pharmaceutical Latest Developments
    • 13.14 Jiangsu Huatai Chenguang Pharmaceutical
      • 13.14.1 Jiangsu Huatai Chenguang Pharmaceutical Company Information
      • 13.14.2 Jiangsu Huatai Chenguang Pharmaceutical Pharmaceutical Grade Dexmedetomidine Hydrochloride Product Portfolios and Specifications
      • 13.14.3 Jiangsu Huatai Chenguang Pharmaceutical Pharmaceutical Grade Dexmedetomidine Hydrochloride Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.14.4 Jiangsu Huatai Chenguang Pharmaceutical Main Business Overview
      • 13.14.5 Jiangsu Huatai Chenguang Pharmaceutical Latest Developments
  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.